What the Regulator Actually Saw: Efficacy Evidence Behind a Registered Label

1. Introduction: the question behind most of this journal

We keep asking what evidence supports a claim that something works. This article asks a narrower version: what did the regulator see before the label was approved.

1.1 Without determining that the claims are warranted

Which is the statute's own phrasing of what a waiver permits.⁵

1.2 What this article argues

That the default was waiver, that the justification rests on an assumption about buyers which fails for our industry, and that where standards do apply they are better than this journal has assumed. Sections 5, 13 and 22 are the case.

2. The statutory permission

Set out above, and worth separating into its two halves.

The agency may waive the data requirement, and having waived it may register the product without making the determination the data would have supported.⁵

2.1 So it is not that efficacy is assessed on weaker evidence

It is that the assessment need not be made.

3. And the rule made under it

Because EPA has waived the requirement for submitting efficacy data for all products except those with public health uses, one section of an application need not contain actual efficacy data, but should include a summary of the results of all efficacy testing performed.³

3.1 The obligation to test survives the obligation to submit

The regulation states that each registrant must ensure through testing that the product is efficacious when used in accordance with label directions and commonly accepted pest control practices.²

3.2 Which is a real distinction and we want to be fair to it

A registrant who does no testing is in breach. What has been removed is external review of the testing, not the requirement to do it.

3.3 And a reserved power remains

The agency reserves the right to require submission of efficacy data on a case-by-case basis.²

4. The reason given

Which is stated in the agency's own notice.

It acted to waive, by regulation, data requirements as to efficacy for all agricultural pesticides, having concluded that agricultural pesticides are effectively regulated by the marketplace, and that waiving efficacy review in registration would let it focus on its primary mandate, investigating the health and safety aspects of pesticides.⁴

4.1 Dated 1979

With the supporting notices running into the early 1980s.⁴

4.2 And the second half of the reason is unobjectionable

Finite review capacity directed at health and safety rather than at performance is a defensible allocation, and we would not argue otherwise.

5. Which is an assumption about the buyer

Our reading of the first half, and the hinge of this article.

For the marketplace to regulate efficacy, the buyer must be able to tell whether the product worked and to act on that judgement in a repeat purchase.

5.1 Which holds well for the case it was written about

A grower applying a herbicide observes the weeds. The outcome is visible, attributable, and arrives within the season, and a product that does not work loses its customers quickly.

5.1b And the mechanism of market discipline needs spelling out

Market discipline on quality requires three things in sequence: the buyer observes the outcome, attributes it to the product, and changes the next purchase. Break any link and the discipline disappears, because a product that fails invisibly keeps its customers.

The agricultural case satisfies all three. That is why the 1979 conclusion was reasonable for what it was written about, and why extending it is the part we question.⁴

5.2 And holds badly for ours

A householder applying a cockroach product observes fewer cockroaches for a while. Populations fluctuate, harbourage empties and refills, the insects are mostly concealed, and the counterfactual is unavailable.

6. And it is the assumption our economics articles dispute

Repeatedly and in other contexts.

Our article on pest control as a credence good argued that buyers cannot verify the quality of what they received even after receiving it, which is precisely the condition under which market discipline on quality fails.

6.1 So the waiver doctrine and our credence-good analysis are the same claim with opposite signs

One says the market can be relied on to police performance. The other says this market specifically cannot.

6.2 Which is a testable disagreement in principle

And we found nothing testing it, in either direction, for structural pest products.

7. What the exceptions cover

And they are drawn around disease rather than around nuisance.

The requirement is waived unless the product bears a claim to control pest microorganisms that pose a threat to human health and whose presence cannot readily be observed by the user, or a claim to control vertebrates such as rodents, birds, bats, canids and skunks that may directly or indirectly transmit diseases to humans.²

7.1 Whose presence cannot readily be observed by the user

Which is the microorganism half of the exception, and it is the observability argument of §5 appearing inside the rule itself.²

7.2 The regulation already knows the principle

Where the buyer cannot see the outcome, the market cannot police it, and data must be submitted. Our objection in §5 is not that the principle is absent but that it was applied to organisms rather than to conditions of observation.

That is ours.

8. Which includes rodent products

A point of direct professional interest.

Rodents appear by name in the vertebrate exception.²

8.0b And the boundary is disease, not damage

A rodent that gnaws wiring and contaminates stored food is inside the exception only because it may also transmit disease. The structural damage this journal has written about at length is not what puts rodent products on the reviewed side of the line.²

8.1 So rodenticide efficacy data has been reviewed

Which places rodent work on a different evidential footing from most insect work, and our anticoagulant articles should be read with that in mind.

9. The 2022 addition

Which narrowed the default considerably.

A final rule established product performance data requirements for products claiming efficacy against certain invertebrate pests, linking the labelling claim to the data needed to substantiate it, for pests of significant public health or economic importance.⁵¹

9.1 And it supersedes the older guidance

The regulations supersede any guidance in the guidelines or registration notices applicable to invertebrate public health pests, including guidance on which species to test or performance standards stated.¹

9.2 With a performance standard in the text

Ninety per cent efficacy appears as the example the agency gives of a standard it may modify on a case-by-case basis.¹⁵

10. What the standards require

And this is where our expectations were wrong.

We came to this expecting to find loose criteria. The criteria are specific, and several of them are stricter than the published pest control literature this journal routinely summarises.

11. The quick kill criteria

To make knockdown, quick kill or kills on contact claims, data should show knockdown within 10 seconds for stinging Hymenoptera (including fire ants) or within 30 seconds for all other arthropods; and mortality by 96 hours post-treatment.¹

11.1 With a time-qualified variant

Similar claims may be made with a time qualification, for example kills quickly within ten minutes, if data show knockdown at the labelled time qualification and mortality by 96 hours.¹

11.2 And controls specified

Under both scenarios treatment groups should be statistically different from control groups, and control mortality should remain at or below 10 per cent.¹

12. Which answers a question we left open

And we should say so plainly, because our previous article implied otherwise.

Our article on pyrethroid knockdown reported a 2026 finding that knockdown does not reliably predict mortality for one compound class, and relayed the authors' concern that using knockdown to substantiate lethality claims may misrepresent efficacy.

12.1 The guidance already requires both endpoints

Knockdown within the threshold and mortality at 96 hours, not one standing in for the other.¹

12.2 So the regulatory gap is narrower than that article implied

What survives of the concern is the wording consumers read rather than the data behind it, and any product for which these requirements were waived or never applied.

That correction is ours and we would rather make it than leave the earlier article standing.

13. And the agency is blunter still

In answer to a question about combining categories.

No. EPA does not consider knocked down or moribund arthropods to be dead (i.e., motionless even when probed).¹

13.1 With the counting rule spelled out

The number of dead, knocked down and live pests in each replicate should be recorded separately at each time point, and a mortality count should include only dead, not knocked down, arthropods.¹

13.2 And moribundity excluded

Moribundity is not used as an endpoint, and if moribund individuals are counted and reported a definition appropriate to the species should be provided, with those individuals not considered dead or included in a mortality count.¹

14. Why that sentence matters

Our assessment.

Motionless even when probed is an operational definition of death written to close the exact gap that a knockdown measurement leaves open, and it is the strictest definition of the endpoint we have encountered anywhere in this journal's reading.¹

14.1 It is stricter than much of the published literature

Papers we have summarised report mortality without stating how death was distinguished from immobility, which this guidance would not accept.

14.1b And it has a cost that explains why others avoid it

Probing every immobile insect individually, at each time point, across the replication scheme in §15, is laborious in a way that scoring a dish at a glance is not. The definition is strict because somebody decided the labour was worth it, and the looser practice elsewhere is not carelessness so much as a different answer to the same cost question.

14.2 And stricter than field practice

A technician judging a treatment by what is lying on the floor is applying the criterion the agency rejects.

15. The design requirements

Balanced designs with equal treatment and control replicates are recommended, using a minimum of five replicates of fifteen individuals, seven of ten, or thirty-five of one, for each treatment, species and surface type, unless justified by a power analysis, with twenty-five replicates of one individual allowed for certain slow-breeding groups though thirty-five remains preferred.¹

15.1 And the protocol must explain the choice

Fully describing how sample size and replication were determined.¹

16. Pseudo-replication, named

With a worked example, which we did not expect to find in regulatory guidance.

Pseudo-replication should be avoided; for example, an experiment in which five petri dishes of insects are sprayed using one sweep of a single aerosol can should not be considered to have five replicates.¹

16.1 That is a real methodological error explained correctly

One application event is one experimental unit regardless of how many dishes were under it.

16.2 And it is an error that appears in published work

Our articles on trial quality have flagged several studies where the unit of randomisation and the unit of analysis appeared to differ. The guidance is ahead of some of the literature on this point.

17. Exposure duration

Which is where the guidance becomes unusually realistic.

Test specimens should be transferred to clean containers after treatment because continuous exposure to a pesticide treatment is not a realistic scenario in most cases.¹

17.1 With numbers

Direct application specimens transferred as soon as practical and no more than fifteen minutes after onset of exposure; for residual studies, crawling pests exposed to treated panels for no more than four hours and flying pests for no more than one hour.¹

18. Which is an objection we raised ourselves

In a different article.

Our piece on pyrethroid temperature effects noted that an insect at low temperature is less active, so contact with a treated surface may fall even as the compound's potency rises, and that this could cancel the laboratory finding in a real residual treatment.

18.1 The guidance builds the same concern into the method

By capping exposure at durations meant to mimic real-world contact rather than allowing unlimited exposure to inflate the result.¹

18.2 Which is a point in the standards' favour we did not anticipate

And it is why §10 says our expectations were wrong.

19. Substrates

Which our article on residual efficacy across surfaces argued were decisive.

For indoor residual treatment both a porous surface, specified as unpainted or unfinished quarter inch plywood, and a nonporous one, glazed ceramic tile, should be used; where fabric, mattresses or carpet are labelled sites, cotton sheeting, mattress ticking or carpeting should also be provided.¹

19.1 With outdoor equivalents

Vinyl siding or tile as nonporous and plywood or unpainted concrete as porous, with concrete used instead of plywood where relevant to the labelled use, and unpainted concrete alone for pavement-only products.¹

19.2 And leaves for plant treatments

Recently collected, from a species easily propagated and common in the use area, clipped as close to the exposure period as practical.¹

20. And the ageing regime

Which is the part our substrate article would have wanted most.

Treated surfaces should be stored outdoors exposed to direct sunlight and precipitation, or aged indoors with simulated outdoor conditions including diel cycles of photoperiod with a light source containing both UVA and UVB and periodic simulated rain, with appropriate temperature and humidity, and the conditions used should mimic those under which the product would typically be used.¹

20.0b And the requirement that conditions mimic actual use

Is the one that would be hardest to satisfy honestly for a product sold across a continent, since the ultraviolet dose, rainfall and temperature under which a perimeter deposit ages in one region bear little relation to another.¹

20.1 Which is a serious specification

Ultraviolet wavelength, rainfall, photoperiod and humidity, rather than a shelf in a laboratory.¹

21. The life stage rule

Short, and with a consequence.

If a proposed labeling claim specifies a pest but not a particular life stage (e.g., "kills fleas"), adults should be used to obtain the claim.¹

22. Which undermines a claim we have written about

Our observation, and it is the sharpest thing in this article.

Our article on the flea pupal window argued that treatment failure in this species is dominated by the pupal stage, which sits inside a cocoon that resists insecticide and from which adults emerge after treatment has been applied.

22.1 A claim reading kills fleas is substantiated against adults

Which is the life stage that was never the difficulty.¹

22.2 So the claim is true and the inference from it is not

The product does kill fleas, meaning adult fleas, under test conditions meeting a defined standard. A householder reads it as a claim about the infestation.

22.2b Which is a general shape worth naming

A claim substantiated against a defined protocol is a claim about that protocol. Where the protocol's conditions differ systematically from the conditions of use, the claim remains true and stops being informative, and nothing in the wording signals which case a reader is in.

That is the same structure as our articles on inspection scores and on uptake data: a measure that is accurate about itself and is read as being about something else.

22.3 And the rule is a sensible default

Some life stage has to be specified where the label does not, and adults are the reasonable choice. We are not saying the rule is wrong. We are saying the gap between what was tested and what is understood is wide and nothing on the label closes it.

23. How the whole apparatus can be set aside

Because everything above is waivable.

Data requirements may be adjusted case by case for novel technologies or atypical use patterns, on a waiver request identifying the requirement and giving a supporting rationale.¹ Performance standards themselves are waivable under the general provision.⁵

23.1 With some friction built in

A modification request must include the data requirement at issue, a detailed explanation and rationale, and efficacy data for all unsuccessful attempts to generate the data, with an applicant's desire to forgo testing typically insufficient on its own.¹

23.2 The failed attempts clause is the interesting one

A registrant asking to be excused from a standard must disclose the tests that did not work, which is a disclosure requirement that publication practice in the open literature does not impose on anybody.

That comparison is ours.

24. And the guidance binds nobody

Stated at the head of the guidance section.

This guidance is not binding on either EPA or any outside party, and the EPA may depart from the guidance where circumstances warrant without prior notice.¹

24.1 Which applies to most of §§11 to 21

The regulations in the 2022 rule are binding; the question-and-answer material elaborating them is not.¹

24.2 So the strictness we have been praising is partly advisory

Recommended practice that a registrant may depart from with a rationale, rather than a floor. That qualification is ours and it should travel with every paragraph above.

25. The Canadian position

Which is structurally different and matters more to us than everything above.

Pesticides here are regulated under the Pest Control Products Act, and before a product can be approved for sale it must be registered, having undergone a pre-market science-based assessment, met health and environmental standards, and must have value.⁷

26. Value as a statutory condition

Not a waivable data requirement.

Only pest control products determined to be of acceptable value are approved for use in Canada, with value defined in the Act as the product's actual or potential contribution to pest management.⁸⁹

26.1 And the applicant carries the burden

An applicant must establish that the product has merit and value for the purposes claimed when used according to label directions, with evaluators carrying out assessments that include determining the efficacy or effectiveness of the product at various doses.⁶

26.2 Companies must supply the studies

Providing all the scientific studies necessary for determining that the product is acceptable in terms of safety, merit and value.⁶

27. What the assessment was said to achieve

And the claimed benefit is not the one we would have guessed.

Assessing efficacy at various doses helps establish the lowest effective rate at which pesticides can be applied, contributing to minimising risks to health and the environment, crop damage and resistance problems, and these assessments were said to have led to many Canadian products carrying up to 50 percent lower label use rates than the same products in other countries.⁶

27.1 Efficacy review as a dose-reduction mechanism

Because a registrant required to demonstrate the lowest effective rate cannot pad the label rate for margin, which is a connection between performance review and exposure reduction we had not considered.

27.2 And a second stated purpose

That efficacy assessments help protect users from deceptive claims regarding the effectiveness of pest control products.⁶

27.3 With a caution about the source

That document is an agency fact sheet from the late 1990s, and the fifty per cent figure is its own characterisation rather than a measured comparison we can check.⁶

28. And how it was loosened

Which narrows the contrast considerably.

A 2010 regulatory proposal set out a more flexible approach to fulfilling value requirements, aiming to facilitate access to new tools, under which information other than the efficacy may be used to determine acceptable value, possibly including evidence of a product's use history in another country and analysis of its potential benefits.¹⁰

28.1 And the current guidance says why

That the definition of value in the Act provides flexibility in fulfilling information requirements, which will help reduce regulatory burden for applicants.⁸

28.2 So value remains mandatory and efficacy data does not

The condition cannot be waived; what satisfies it can be something other than a performance study.¹⁰

29. Two regimes converging

One began by waiving efficacy review on a market-discipline rationale and has since added binding performance requirements for named invertebrate pests.⁴⁵ The other began with a statutory value requirement and has since permitted non-efficacy information to satisfy it.¹⁰

29.1 Which is our reading rather than anyone's stated position

Neither regulator describes itself as moving toward the other, and the two changes were made decades apart for unrelated reasons.

29.1b And the two movements had different motives

One was a reallocation of scarce review capacity toward health and safety. The other was explicitly a burden reduction for applicants, aimed at speeding access to new products.⁴⁸

Which matters for how each is likely to develop, since a capacity argument reverses when capacity grows and a burden argument does not.

29.2 The practical difference that remains

A Canadian registration carries an affirmative finding of acceptable value on the record. An American registration may carry no efficacy finding at all.⁵⁸

30. The device question

Which bears directly on an article we have already written.

A regulatory consultancy describes misleading claims about pesticide devices as having been prevalent, the pre-2022 device regulations as out of date and difficult to update, and a June 2022 amendment as giving clearer definitions of which devices require registration, with registrants now having to provide a complete dataset addressing value requirements.¹¹

30.1 With a gap the same source names

That specific guidelines to prove a device's performance have not yet been published, with the agency suggesting the antimicrobial value guidelines as a starting point.¹¹

30.2 Which is the regulatory backdrop to our consumer devices article

That article found the efficacy evidence for ultrasonic and similar products absent. This supplies the mechanism: a device category whose claims went essentially unexamined until recently and for which performance guidelines were still not published at the time our source was written.¹¹

30.3 The source is a commercial one

Written by a testing consultancy whose business is helping registrants meet these requirements, and we treat its characterisation of the history accordingly.¹¹

31. What we take from this

Three things, and the first is a correction.

The standards are better than we assumed. Sections 13 to 20 describe endpoint definitions, replication rules, exposure caps and ageing regimes stricter than much of the literature this journal summarises.¹

The question is which products they touched. Not whether good standards exist but whether a given registration was assessed against them.²³

And a label claim describes a test, not an outcome. Section 22 is the clearest case: kills fleas is a true statement about adults under a defined protocol and is read as a statement about an infestation.

32. Our own position

The disclosure.

We apply registered products and quote their labels to clients, and §22 says the gap between what was tested and what a client understands is wide. Closing it is our job rather than the label's.

32.1 And one conclusion here is convenient for us

That Canadian registrations carry an affirmative value finding is a point in favour of the regulatory regime we operate under, and we note that we would have reported the opposite finding with the same prominence.

33. Limitations and open questions

The American material is primary and the Canadian material mostly is not. The efficacy guidance, the regulation and the registration notice are agency documents read directly, while several Canadian points come from agency presentations and an old fact sheet.⁶⁹¹⁰

Two Canadian sources are conference presentations. Slide decks by agency staff, hosted on a foreign regulator's archive, which is weak sourcing for the flexibility point in §28 and the value definition in §26.⁹¹⁰

That is the most important weakness because §§28 and 29 turn on how far the Canadian value requirement has been relaxed, and we established that from a 2010 proposal summarised in a slide rather than from the instrument itself.

We did not read the 2022 rule. Subpart R is cited through the agency's own summary of it and through the rule's preamble in the federal register, not through the codified text.⁵

Nor the current Canadian value guidance in full. We have its table of contents, its statement of purpose and its rationale, and not the substantive requirements.⁸

And we could not establish what applies to structural insecticides in Canada specifically. Whether a cockroach or bed bug product faces requirements comparable to the American invertebrate rule is exactly the question a Manitoba contractor would want answered, and we could not answer it.

Sections 5, 6, 7.2, 12, 14, 16.2, 18, 22, 23.2, 24.2, 27.1, 29 and 31 are our reasoning. The observability argument against the market-discipline rationale, the correction to our own pyrethroid article, the flea life-stage consequence, the reading of the failed attempts clause and the convergence framing are ours rather than sourced positions.

34. Conclusion

The American statute permits waiving efficacy data, in which event a pesticide may be registered without the agency determining that its composition warrants the proposed claims.⁵ The agency waived those requirements by rule, on the stated conclusion that agricultural pesticides are effectively regulated by the marketplace, so that review capacity could go to health and safety instead.⁴ That rationale depends on the buyer being able to observe whether the product worked, which holds for a grower looking at a field and fails for a householder looking at a kitchen. The regulation already contains the principle: the exception for microorganisms is written around pests whose presence cannot readily be observed by the user.² It was drawn around organisms rather than around conditions of observation, which is our objection to it.

Where standards apply they are better than we expected. A quick kill claim needs knockdown within 10 or 30 seconds by pest group and mortality at 96 hours, with treatment groups statistically different from controls and control mortality at or below 10 per cent. The agency states that it does not consider knocked down or moribund arthropods to be dead, defining death as motionless even when probed, and requires dead, knocked down and live insects to be counted separately.¹ It names pseudo-replication and gives a worked example of it, caps exposure durations because continuous exposure is unrealistic, and specifies substrates and an ageing regime down to ultraviolet wavelength and simulated rain. Several of these are stricter than the published work this journal routinely summarises, and the knockdown-mortality distinction substantially answers a concern we raised in our previous article.¹

What survives is narrower and still matters. The guidance elaborating the binding rule is not itself binding, and the standards are waivable on a rationale. Canada requires acceptable value as a statutory condition for every product, which is a real structural difference, but permits information other than efficacy to satisfy it, so the two regimes have moved toward each other from opposite starting points.⁸¹⁰ And the sharpest thing we found is the smallest: where a claim names a pest without a life stage, adults are tested. A product labelled as killing fleas has been shown to kill adult fleas, which our own article argued is the stage that was never the problem. The claim is true. What a householder concludes from it is not the claim.

References

1. Efficacy testing for pesticides targeting certain invertebrate pests. Agency guidance page published by the United States Environmental Protection Agency, read in full. Source for the statement that the regulations in the 2022 subpart supersede guidance in the guidelines or registration notices applicable to invertebrate public health pests including guidance on which species to test or performance standards stated; for the waiver procedure, requiring a request identifying the data requirement, an explanation and supporting rationale, and efficacy data for all unsuccessful attempts to generate the data, with an applicant's desire to forgo testing typically insufficient on its own, and for the statement that performance standards such as ninety per cent efficacy may be modified case by case; for the statement that the guidance is not binding on either the agency or any outside party and that the agency may depart from it without prior notice; for the knockdown, quick kill and kills on contact criteria, namely knockdown within 10 seconds for stinging Hymenoptera including fire ants or within 30 seconds for all other arthropods and mortality by 96 hours post-treatment, with the time-qualified variant, the requirement that treatment groups be statistically different from control groups and that control mortality remain at or below 10 per cent; for the statement that the agency does not consider knocked down or moribund arthropods to be dead, defined as motionless even when probed, with dead, knocked down and live pests recorded separately and a mortality count including only dead arthropods, and moribundity excluded as an endpoint; for the substrate specifications for indoor residual, outdoor perimeter, pavement and plant treatments, and the ageing regime requiring outdoor storage exposed to sunlight and precipitation or indoor simulation with diel photoperiod cycles using a light source containing UVA and UVB and periodic simulated rain; for the life stage rule that where a claim specifies a pest but not a life stage, adults should be used; for the replication recommendations, the allowance for certain slow-breeding groups, the requirement that the protocol describe how sample size and replication were determined, and the statement that pseudo-replication should be avoided with the worked example of five petri dishes sprayed in one sweep of a single aerosol can; and for the transfer requirement, that specimens be moved to clean containers because continuous exposure is not a realistic scenario, within fifteen minutes for direct application, with residual exposure capped at four hours for crawling pests and one hour for flying pests. https://www.epa.gov/pesticide-registration/efficacy-testing-pesticides-targeting-certain-invertebrate-pests
2. Data requirements for pesticides, part 158 of title 40 of the American code of federal regulations, read as the current electronic text. Source for the statement that the agency has waived the requirement to submit efficacy data unless the product bears a claim to control pest microorganisms that pose a threat to human health and whose presence cannot readily be observed by the user, or a claim to control vertebrates such as rodents, birds, bats, canids and skunks that may directly or indirectly transmit diseases to humans; for the accompanying statement that each registrant must nonetheless ensure through testing that the product is efficacious when used in accordance with label directions and commonly accepted pest control practices; and for the agency's reservation of the right to require submission of efficacy data on a case-by-case basis. https://www.ecfr.gov/current/title-40/chapter-I/subchapter-E/part-158
3. Pesticide registration manual, chapter on experimental use permits, published by the same agency. Source for the statement that because the agency has waived the requirement for submitting efficacy data for all products except those with public health uses, the relevant application section need not contain actual efficacy data but should include a summary of the results of all efficacy testing performed. https://www.epa.gov/pesticide-registration/pesticide-registration-manual-chapter-12-applying-experimental-use-permit
4. Pesticide registration notice 96-4, on label statements involving product efficacy and potential for harm to property, published by the same agency. Source for the account that the agency acted under its statutory authority to waive by regulation the data requirements as to efficacy for all agricultural pesticides, citing federal register notices from 1979 and the early 1980s, having concluded that agricultural pesticides are effectively regulated by the marketplace and that waiving efficacy review in the registration process would enable the agency to focus on its primary mandate of investigating the health and safety aspects of pesticides. https://www.epa.gov/pesticide-registration/prn-96-4-label-statements-involving-product-efficacy-and-potential-harm
5. Pesticide product performance data requirements for products claiming efficacy against certain invertebrate pests. Final rule preamble published in the American federal register, read as an extract rather than as the codified regulatory text. Source for the quotation of the statutory provision that the agency may waive data requirements pertaining to efficacy, in which event the administrator may register the pesticide without determining that the pesticide's composition is such as to warrant proposed claims of efficacy; for the rule's description of itself as identifying the data requirements typically necessary to determine whether proposed claims of efficacy are warranted, with opportunity for waiver or modification; for the statement that the data needs link the labelling claim for products claiming efficacy against an invertebrate pest with the data needed to substantiate that claim; for the statement that the agency views these standards as performance standards for the acceptability of data and that they are waivable; and for the discussion of a ninety per cent performance standard and the flexibility to modify data requirements for novel technologies or products with unusual properties or atypical use patterns. https://www.federalregister.gov/documents/2022/04/15/2022-07963/pesticide-product-performance-data-requirements-for-products-claiming-efficacy-against-certain
6. Fact sheet on the regulation of pesticides, published by Canada's Pest Management Regulatory Agency in the late 1990s and read as a government publications archive document. An agency document of its period, and we flag its age because the figure we take from it is its own characterisation rather than a measured comparison. Source for the statement that an applicant for registration must establish that the product has merit and value for the purposes claimed when used according to label directions, that agency evaluators carry out these assessments including determining the efficacy or effectiveness of the product at various doses, that this helps establish the lowest effective rate at which pesticides can be applied and contributes to minimising risks to health and the environment, crop damage and resistance problems; for the claim that these assessments have led to many Canadian products having up to 50 percent lower label use rates than the same products in other countries; for the statement that efficacy assessments help protect users from deceptive claims regarding effectiveness; and for the statement that companies must provide all the scientific studies necessary for determining that a product is acceptable in terms of safety, merit and value, with a complete evaluation taking from weeks to a year or more. https://publications.gc.ca/collections/Collection/H113-2-2-1999E.pdf
7. Regulations amending the Pest Control Products Regulations, regulatory impact material published in the Canada Gazette in 2022. Source for the statement that before a pest control product can be approved for use and marketed in Canada it must be registered or otherwise authorised under the Act, and that in order to be registered products must undergo a thorough pre-market science-based assessment, meet health and environmental standards, and must have value. https://gazette.gc.ca/rp-pr/p1/2022/2022-06-11/html/reg4-eng.html
8. Value assessment of pest control products. Guidance document published by Canada's regulator, read as its executive summary, purpose section and table of contents rather than in full. Source for the statement that in accordance with the Act only pest control products determined to be of acceptable value are approved for use in Canada; for the definition of value as the product's actual or potential contribution to pest management; for the statement that consideration of the statutory definition of value provides flexibility in fulfilling information requirements which will help reduce regulatory burden for applicants and provide opportunities for international alignment; and for the indication that the guidance came into effect in March 2022 for applications submitted on or after 1 April 2022, superseding an earlier directive. https://www.canada.ca/en/health-canada/services/consumer-product-safety/reports-publications/pesticides-pest-management/policies-guidelines/value-assessment-pest-control-products.html
9. Presentation on efficacy data requirements for biopesticide registration in Canada, given by a staff member of the Canadian regulator's value and sustainability directorate and archived by the American regulator. A conference slide deck rather than a published guidance instrument, flagged as such. Source for the quotation of the statutory position that only pest control products determined to be of acceptable value are approved for use in Canada, and for the definition of value as a product's actual or potential contribution to pest management. https://archive.epa.gov/pesticides/biopesticides/web/pdf/17-lilian-deluna.pdf
10. Presentation on the Canadian registration submission and decision process, given by a staff member of the Canadian regulator and archived by the American regulator. A conference slide deck, flagged as such and carrying the weakest sourcing in this article. Source for the summary of a November 2010 regulatory proposal setting out a more flexible approach to fulfilling the value requirements for registration, aimed at facilitating access to new and effective crop protection tools, under which information other than the efficacy may be used to determine acceptable value, possibly including evidence of a product's use history in another country and analysis of its potential benefits. https://archive.epa.gov/pesticides/biopesticides/web/pdf/7-terry-caunter.pdf
11. Article on supporting pesticide device efficacy claims in Canada, published by a testing and certification consultancy whose business includes helping registrants meet these requirements. Commercial material, cited as attributed material and treated accordingly. Source for the characterisation that misleading device claims were prevalent and extremely misleading to consumers, that the pre-existing device regulations had become a relic, out of date and difficult and time consuming to update, that a June 2022 amendment gave clearer definitions of which devices require registration, that registrants must provide a complete dataset addressing value assessment requirements and essentially prove the device works as intended, and that specific guidelines to prove a device's performance had not yet been published, with the regulator suggesting the antimicrobial value guidelines as a starting point. https://www.intertek.com/blog/2023/05-16-pesticide-device-efficacy/